Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collegium Pharmaceutical
Collegium Pharmaceutical announces development milestone under Cypress Bioscience agreement
July 4th, 2006
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced the achievement of a development milestone that is a subject of the Reformulation and New Product Agreement with Cypress Bioscience, Inc. In January of 2004, Collegium was paid a development milestone when Cypress exercised its option to license all of the intellectual property rights from Collegium for novel reformulations and new analogs of milnacipran developed by Collegium under the companies' Reformulation and New Product Agreement entered into in August 2002. The goal of the collaboration is to develop competitive follow-on products to milnacipran thereby extending Cypress' milnacipran...
Source: Pharma Law Weekly (2006-07-04)
|
